Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

References

• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• EscudierBJPluzanskaAKoralewskiPRavaudABevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200837096052103211118156031
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• HudesGRCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBJOudardSPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• CoppinCKollmannsbergerCLeLPorzsoltFWiltTJTargeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trialsBJU Int2011108101556156321952069
   PubMed Web of Science ®Google Scholar
• RiniBIMichaelsonMDRosenbergJEAntitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaJ Clin Oncol200826223743374818669461
   PubMed Web of Science ®Google Scholar
• PortaCProcopioGCartenìGSequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesBJU Int20111088 Pt 2E250E25721599821
   PubMed Web of Science ®Google Scholar
• Di LorenzoGCartenìGAutorinoRPhase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancerJ Clin Oncol200927274469447419652053
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• LinehanWMWaltherMMZbarBThe genetic basis of cancer of the kidneyJ Urol20031706 Pt 12163217214634372
   PubMed Web of Science ®Google Scholar
• ZhuangZGnarraJRDudleyCFZbarBLinehanWMLubenskyIADetection of von Hippel-Lindau disease gene mutations in paraffin-embedded sporadic renal cell carcinoma specimensMod Pathol1996988388428871925
   PubMed Web of Science ®Google Scholar
• IliopoulosOKibelAGraySKaelinWGTumour suppression by the human von Hippel-Lindau gene productNat Med1995188228267585187
   PubMed Web of Science ®Google Scholar
• PatardJ-JPignotGEscudierBICUD-EAU international consultation on kidney cancer 2010: treatment of metastatic diseaseEur Urol201160468469021704448
   PubMed Web of Science ®Google Scholar
• LjungbergBCowanNCHanburyDCEAU guidelines on renal cell carcinoma: the 2010 updateEur Urol201058339840620633979
   PubMed Web of Science ®Google Scholar
• RiniBIWildingGHudesGPhase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaJ Clin Oncol200927274462446819652060
   PubMed Web of Science ®Google Scholar
• WeikertSKempkensteffenCBuschJSequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitorsWorld J Urol2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• AmatoRJJacJGiessingerSSaxenaSWillisJPA phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancerCancer2009115112438244619306412
   PubMed Web of Science ®Google Scholar
• MackenzieMJRiniBIElsonPTemsirolimus in VEGF-refractory metastatic renal cell carcinomaAnn Oncol201122114514820595449
   PubMed Web of Science ®Google Scholar
• ChowLQMEckhardtSGSunitinib: from rational design to clinical efficacyJ Clin Oncol200725788489617327610
   PubMed Web of Science ®Google Scholar
• WickmanGHallinMDillonRFurther characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor, AG013736, in preclinical tumor models for its antiangiogenesis and antitumor activityProc Am Assoc Cancer Res200344A3780
   Google Scholar
• InaiTMancusoMHashizumeHInhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghostsAm J Pathol20041651355215215160
   PubMed Web of Science ®Google Scholar
• MancusoMRDavisRNorbergSMRapid vascular regrowth in tumors after reversal of VEGF inhibitionJ Clin Invest2006116102610262117016557
   PubMed Web of Science ®Google Scholar
• RugoHSHerbstRSLiuGPhase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical resultsJ Clin Oncol200523245474548316027439
   PubMed Web of Science ®Google Scholar
• BrennanMWilliamsJAChenYTortoriciMPithavalaYLiuYCMeta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokineticsEur J Clin Pharmacol201268564565522170007
   PubMed Web of Science ®Google Scholar
• TortoriciMATohMRahavendranSVInfluence of mild and moderate hepatic impairment on axitinib pharmacokineticsInvest New Drugs20112961370138020596748
   PubMed Web of Science ®Google Scholar
• MorganBThomasALDrevsJDynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studiesJ Clin Oncol200321213955396414517187
   PubMed Web of Science ®Google Scholar
• FlahertyKTRosenMAHeitjanDFPilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinomaCancer Biol Ther20087449650118219225
   PubMed Web of Science ®Google Scholar
• HahnOMYangCMedvedMDynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinomaJ Clin Oncol200826284572457818824708
   PubMed Web of Science ®Google Scholar
• LiuGRugoHSWildingGDynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I studyJ Clin Oncol200523245464547316027440
   PubMed Web of Science ®Google Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst2011103976377321527770
   PubMed Web of Science ®Google Scholar
• RiniBISchillerJHFruehaufJPDiastolic blood pressure as a biomarker of axitinib efficacy in solid tumorsClin Cancer Res201117113841384921531811
   PubMed Web of Science ®Google Scholar
• RixeOBukowskiRMMichaelsonMDAxitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II studyLancet Oncol200781197598417959415
   PubMed Web of Science ®Google Scholar
• KrajewskiKMGuoMvan den AbbeeleADComparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinomaEur Urol201159585686221306819
   PubMed Web of Science ®Google Scholar
• MotzerRJde La Motte RougeTHarzstarkALAxitinib second- line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trialJ Clin Oncol201129SupplAbstr 4547
   Google Scholar
• EscudierBLoomisAKKaprinAAssociation of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure (BP) in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib versus sorafenib (AXIS Trial)Eur J Cancer201147Suppl 1Abstr 7103
   Google Scholar
• MotzerRJEscudierBJOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• GrünwaldVSoltauJIvanyiPRentschlerJReuterCWMDrevsJMolecular targeted therapies for solid tumors: management of side effectsOnkologie200932312913819295254
   PubMedGoogle Scholar
• HorowitzJRRivardAvan der ZeeRVascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endotheliumArterioscler Thromb Vasc Biol19971711279328009409257
   PubMed Web of Science ®Google Scholar
• MukoharaTNakajimaHMukaiHEffect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patientsCancer Sci2010101496396820180805
   PubMed Web of Science ®Google Scholar
• BuschJSeidelCKempkensteffenCSequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitorsEur Urol20116061163117021802830
   PubMed Web of Science ®Google Scholar
• BuschJSeidelCWeikertSIntrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinomaBMC Cancer201111129521756335
   PubMed Web of Science ®Google Scholar
• HengDYCXieWBjarnasonGAProgression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapyCancer2011117122637264221656741
   PubMed Web of Science ®Google Scholar